Aspira Womens HealthAWHL +7.07%36 EV-to-FCF is -5.27 as of Jul. 03, 2026. GuruFocus rates AWHL with a GF Score™ of 36/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 98 Medical Diagnostics & Research companies, Aspira Womens Health ranks worse than 1020407.14% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Aspira Womens Health's Enterprise Value is $22.57 Mil.
Aspira Womens Health's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-4.29 Mil. Therefore, Aspira Womens Health's EV-to-FCF for today is -5.27.
The historical rank and industry rank for Aspira Womens Health's EV-to-FCF or its related term are showing as below:
AWHL'
s EV-to-FCF Range Over the Past 10 Years
Min: -61.76 Med: -3.31 Max: -0.03
Current: -5.27
During the past 13 years, the highest EV-to-FCF of Aspira Womens Health was -0.03. The lowest was -61.76. And the median was -3.31.
AWHL's EV-to-FCF is ranked worse than 100% of 98
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.975
vs AWHL: -5.27
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Aspira Womens Health (OTCPK:AWHL) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Aspira Womens Health's PE Ratio (TTM) for today is calculated as:
Aspira Womens Health's share price for today is $0.42.
Aspira Womens Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.320.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Aspira Womens Health EV-to-FCF Related Terms
Aspira Womens Health EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Aspira Womens Health's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Aspira Womens Health's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspira Womens Health EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Aspira Womens Health's EV-to-FCF falls into.
Aspira Womens Health's current Enterprise Value is $22.57 Mil.
Aspira Womens Health's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.29 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspira Womens Health (AWHL) has a EV-to-FCF of -5.27 as of Jul. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Aspira Womens Health and its competitors. According to the industry distribution chart, Aspira Womens Health ranks #999999 out of 98 companies in the Medical Diagnostics & Research industry.
Is Aspira Womens Health's EV-to-FCF too high?
Aspira Womens Health's current EV-to-FCF is -5.27. Based on the distribution chart, Aspira Womens Health ranks #999999 out of 98 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Aspira Womens Health has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aspira Womens Health's EV-to-FCF compare to MDXH and BIOQ?
According to the Medical Diagnostics & Research industry distribution chart, Aspira Womens Health ranks #999999 out of 98 companies for EV-to-FCF. This places Aspira Womens Health in the lower half of its industry. The industry median EV-to-FCF is 22.98. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 22.98, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Aspira Womens Health and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 22.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspira Womens Health's current EV-to-FCF is -5.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspira Womens Health stock overvalued right now?
Based on GuruFocus' analysis, Aspira Womens Health (AWHL) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $0.42 — trading 50% above its estimated fair value. The current EV-to-FCF is -5.27. Aspira Womens Health's overall GF Score™ is 36/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Aspira Womens Health (AWHL), the current EV-to-FCF is -5.27 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspira Womens Health (AWHL) Overvalued in 2026?
Based on GuruFocus' analysis, Aspira Womens Health stock appears to be overvalued.
The current stock price of $0.42 is trading 50% above its estimated GF Value™ of $0.28.
GuruFocus considers Aspira Womens Health to be Significantly Overvalued.
Key valuation signals for AWHL:
EV-to-FCF: -5.27
GF Value™: $0.28 vs. price of $0.42 (50% above fair value)
No single metric tells the full story. See the AWHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its main products include OvaWatch, Ova1Plus, Ova1, and Overa, which are used to assess ovarian cancer risk in women with adnexal masses. The company is also developing EndoCheck for endometriosis. The company views its operations and manages its business in a single operating segment, which is the discovery, development, and commercialization of noninvasive diagnostic tests.
36GF Score
Get the complete analysis for AWHL
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AWHL has been successfully added to your 
